SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals informs about letter for weblink for annual report

08 Jun 2026 Evaluate
In terms of the requirements of Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, GlaxoSmithKline Pharmaceuticals has informed that the Company has issued letters to those Shareholder’s whose e-mail addresses are not registered with the Company/Depository Participants, providing the weblink from where the Annual Report can be accessed on the Company’s website. The letter in this regard is enclosed.

The above information is a part of company’s filings submitted to BSE.  

Glaxosmithkline Phar Share Price

2183.00 16.70 (0.77%)
08-Jun-2026 15:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1788.90
Dr. Reddys Lab 1276.30
Cipla 1383.85
Zydus Lifesciences 1088.00
Lupin 2254.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×